Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.
Tiotropium was granted FDA approval on 30 January 2004.
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 934
- Registration Number
- NCT01574651
- Locations
- 🇩🇪
Novartis Investigative Site, Zerbst, Germany
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 219
- Registration Number
- NCT01559116
- Locations
- 🇧🇪
1237.20.32201 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱1237.20.31204 Boehringer Ingelheim Investigational Site, Hengelo, Netherlands
🇭🇺1237.20.36201 Boehringer Ingelheim Investigational Site, Szarvas, Hungary
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 295
- Registration Number
- NCT01533922
- Locations
- 🇺🇸
1237.13.01307 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
🇺🇸1237.13.01305 Boehringer Ingelheim Investigational Site, Easley, South Carolina, United States
🇦🇹1237.13.43303 Boehringer Ingelheim Investigational Site, Linz, Austria
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
- Conditions
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 291
- Registration Number
- NCT01533935
- Locations
- 🇨🇦
1237.14.11404 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇦🇹1237.14.43402 Boehringer Ingelheim Investigational Site, Grieskirchen, Austria
🇦🇹1237.14.43401 Boehringer Ingelheim Investigational Site, Neumarkt am Wallersee, Austria
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 247
- Registration Number
- NCT01490125
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
- Conditions
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 140
- Registration Number
- NCT01483625
- Locations
- 🇺🇸
205.479.01037 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸205.479.01007 Boehringer Ingelheim Investigational Site, Easley, South Carolina, United States
🇺🇸205.479.01002 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 414
- Registration Number
- NCT01462929
- Locations
- 🇵🇱
Almirall Investigational Site #14, Tarnow, Poland
🇵🇱Almirall Investigational Site #17, Krakow, Poland
🇩🇪Almirall Investigational Site #9, Frankfurt, Germany
Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China
- Conditions
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2016-08-11
- Target Recruit Count
- 841
- Registration Number
- NCT01455129
- Locations
- 🇨🇳
Guangdong No.2 Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Shaoguan Iron and Steel Group Company limited Hospital, Shaoguan, Guangdong, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2539
- Registration Number
- NCT01431287
- Locations
- 🇸🇰
1237.6.42106 Boehringer Ingelheim Investigational Site, Zilina, Slovakia
🇿🇦1237.6.27002 Boehringer Ingelheim Investigational Site, Bellville, South Africa
🇺🇸1237.6.01129 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2624
- Registration Number
- NCT01431274
- Locations
- 🇺🇸
1237.5.01028 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States
🇨🇿1237.5.42005 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇫🇮1237.5.35802 Boehringer Ingelheim Investigational Site, Turku, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.